Neuronetics Inc

STIM remains in a Stage 2 uptrend with clear higher highs and higher lows above rising EMAs, but an Extreme Overbought RSI and active Bullish Exhaustion at resistance argue for patience. The 200-day SMA caps rallies while the support cluster around the 20-EMA/50-SMA has held. Medium-term bias is bullish, yet execution is best deferred to a pullback into EMAs and structural support before participation.

• ↑84% YoY revenue growth to $32M in Q1 2025 via Greenbrook integration.
• ↑Achieved positive $0.9M operating cash flow in Q4 2025 through cost management.
• ↓Negative earnings yield suggests valuation misalignment with growth.